subject: Stocks To Watch From Pennytobuck.com: Dtsl, Fedex, Prot, Arqule [print this page] Delivery Technology Solutions, IncDelivery Technology Solutions, Inc. (PINK SHEETS:DTSL) and its subsidiary Universal Delivery Solutions, Inc. (http://www.universaldelivery.com) management hosted a successful shareholder teleconference on August 9, 2010, revealing several important company updates.
CFO Jeff Smith opened the conference by addressing participants about DTSL's history and detailed how UDS' customized chain delivery system has already been adopted by a major American fast food retailer and a national movie theatre chain.
According to DTSL's CFO Jeff Smith, the company expects to realize a 100% revenue increase in Q3 over Q2 of this year, and another 100% increase in Q4 over Q3. He forecasted 2010 revenue at $400,000 to $500,000, with 2011 revenue expected to more than double this year's total.
Mr. Jeff Smith has stated to his investors that DTSL would explore every opportunity to market and raise awareness of the UDS delivery system, and the long-time shareholders showed excitement for DTSL to realize its potential by breaking away from the sub-penny values into penny lands. With this success, DTSL sees the potential to eventually move up to a higher stock exchange.
PROTEONOMIX, INC. (OTCBB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the PROT investment opportunity to institutional investors.
The trip is scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.).
Mr. Cohen will also discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
In their release from August 17th, 2010, their recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC., a Nevis Island limited liability company.
PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products.
To receive additional information about PROT, please visit the website at http://www.proteonomix.com/
The Board of Directors of FedEx Corporation (NYSE:FDX) recently declared a quarterly cash dividend of $0.12 per share on FDX common stock. The dividend is payable October 1, 2010 to stockholders of record at the close of business on September 10, 2010.
FedEx Corporation provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services. With annual revenues of $35 billion, FDX offers integrated business applications through operating companies competing collectively and managed collaboratively, under the respected FedEx brand. Consistently ranked among the world's most admired and trusted employers, FedEx inspires its more than 280,000 team members to remain "absolutely, positively" focused on safety, the highest ethical and professional standards and the needs of their customers and communities. For more information, visit news.fedex.com.
FedEx Ground has announced one of its highest honors for three entrepreneurs whose businesses provide package delivery services for the company. Steve Crawford (Steve Crawford Trucking, St. Louis, Mo.), Bruce Eucce (Bruce Eucce Transportation, Ventura, Calif.) and Nicole Huffman (A.R. Huffman, Inc., Dayton, Ohio) were named FedEx Ground Entrepreneurs of the Year at a banquet recognizing them for their business development, customer service results, safety record and community support. Of the nearly 12,000 small-delivery businesses that support the FedEx Ground network, Crawford, Eucce and Huffman were selected from a group of 22 finalists who represented the best for fiscal year ending May 31, 2010.
The FedEx Ground Entrepreneur of the Year honor was established in 2007 to recognize business men and women who have built businesses that most consistently go the extra mile to safely deliver superior customer service, help fellow delivery business owners succeed, and support their local communities. Since the founding of the Entrepreneur of the Year program, FedEx Ground has named 428 regional honorees.
For more information on FDX visit their site at www.fedex.com
ArQule, Inc. (NASDAQ:ARQL) recently reported its financial results for the second quarter of 2010.
For the quarter ended June 30, 2010, ARQL reported a net loss of $8,227,000 or $0.18 per share, compared with a net loss of $8,272,000 or $0.19 per share, for the second quarter of 2009. For the six-month period ended June 30, 2010, the Company reported a net loss of $17,979,000 or $0.40 per share, compared to a net loss of $18,180,000 or $0.41 per share, for the six-month period ended June 30, 2009.
At June 30, 2010, ARQL had a total of approximately $111,738,000 in cash, equivalents and marketable securities, which includes $16,200,000 drawn down in 2008 under notes payable that are collateralized by ARQLs auction rate securities. Net of these notes, at June 30, 2010, ARQL had a total of $95,538,000.
On July 2, 2010, ARQL retired the notes payable at June 30, 2010 under its revolving credit line agreement with UBS AG following the redemption at par value of all $22.9 million of ARQLs auction rate securities that had been brokered by UBS AG.
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. ARQLs targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ARQLs lead product, in Phase 2 and upcoming Phase 3 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase.
To receive additional information about ARQL, please visit the website at http://www.arqule.com
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty-five thousand dollars in cash from a third party (Ceiba Network/PenStox) for (30) days of advertising for Delivery Technology Solutions, Inc. (DTSL.PK)Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
